SMS Pharmaceuticals Share Price

Overview
Recos
News
Analysis
Financials
Forecast
Technicals
Peers
Shareholdings
MF
F&O
Corp Actions
About

SMS Pharmaceuticals Share Price

378.604.46 (1.19%)

Closed
As On: 19 Jun, 2026, 03:54 PM IST
As On: 19 Jun, 2026, 03:40 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Try ETMarkets GPTNEW

Open	374.40
High	386.00
Low	373.15
Prev Close	374.15
Volume	1,03,827
VWAP(₹)	379.70

Key Metrics

PE Ratio(x)	34.77
EPS - TTM(₹)	10.89
MCap(₹ Cr.)	3,545.67
MCap Rank	67
PB Ratio(x)	4.46
Div Yield(%)	0.11
Face Value(₹)	1.00
52W High(₹)	447.80
52W Low(₹)	207.70
MCap/Sales	3.96
Beta(1 Month)	0.30
BV/Share(₹)	83.91

SMS Pharma share price insights

ROE Outperforming 5 Year Average
Company delivered ROE of 12.97% in year ending Mar 31, 2026 outperforming its 5 year avg. of 9.55%. (Source: Consolidated Financials)
Employee & Interest Expense
Company has spent 2.6% of its operating revenues towards interest expenses and 9.92% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)
Increase in Cash from Investing
Company has used Rs 130.78 cr for investing activities which is an YoY increase of 5.96%. (Source: Consolidated Financials)
SMS Pharma Share Price Update
SMS Pharmaceuticals Ltd. share price moved up by 1.19% from its previous close of Rs 374.15. SMS Pharmaceuticals Ltd. stock last traded price is 378.60
Share Price Value
Today/Current/Last 378.60376.90
Previous Day 374.15374.35

Found Insights useful?

SMS Pharma Share Price Returns

1 Day	1.19%
1 Month	-7.71%
3 Months	3.41%
1 Year	66.71%
3 Years	310.85%
5 Years	121.86%

SMS Pharma Share Recommendations

No Recommendations details available for this stock.
Check out other stock recos.

News & Analysis

View all SMS Pharma Share News & Announcements

Share Analysis

EARNINGS

FUNDAMENTAL

RELATIVE VALUATION

RISK

PRICE MOMENTUM

Unlock Stock Score, Analyst' Ratings & Recommendations

Score on 10-point scale
Ratings by analysts
Stock performance

JOIN ET PRIME

Financials

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	240.52	214.20	243.86	196.64	249.62
Total Income Growth (%)	12.29	-12.16	24.02	-21.22	42.25
Total Expenses	208.18	176.82	204.09	166.43	216.03
Total Expenses Growth (%)	17.74	-13.36	22.62	-22.96	45.14
EBIT	32.34	37.38	39.78	30.21	33.59
EBIT Growth (%)	-13.48	-6.02	31.67	-10.06	26.08
Profit after Tax (PAT)	32.71	23.47	25.31	20.49	20.32
PAT Growth (%)	39.37	-7.27	23.53	0.86	11.37
EBIT Margin (%)	13.45	17.45	16.31	15.36	13.46
Net Profit Margin (%)	13.60	10.96	10.38	10.42	8.14
Basic EPS (₹)	3.58	2.59	2.84	2.31	2.40

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	240.52	214.20	243.86	196.64	249.62
Total Income Growth (%)	12.29	-12.16	24.02	-21.22	42.25
Total Expenses	208.20	176.67	204.07	166.94	215.49
Total Expenses Growth (%)	17.85	-13.43	22.24	-22.53	44.87
EBIT	32.32	37.53	39.79	29.70	34.13
EBIT Growth (%)	-13.88	-5.68	33.97	-12.97	27.66
Profit after Tax (PAT)	20.92	23.34	25.14	18.21	20.62
PAT Growth (%)	-10.36	-7.18	38.09	-11.71	20.09
EBIT Margin (%)	13.44	17.52	16.32	15.10	13.67
Net Profit Margin (%)	8.70	10.90	10.31	9.26	8.26
Basic EPS (₹)	2.29	2.57	2.82	2.05	2.43

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	895.22	788.97	713.72	526.94	525.07
Total Revenue Growth (%)	13.47	10.54	35.45	0.36	-7.33
Total Expenses	778.59	696.64	647.62	521.59	456.57
Total Expenses Growth (%)	11.76	7.57	24.16	14.24	-3.98
Profit after Tax (PAT)	101.99	69.14	49.83	-7.06	62.22
PAT Growth (%)	47.52	38.75	-	-111.35	-0.49
Operating Profit Margin (%)	15.75	14.16	12.62	5.22	16.80
Net Profit Margin (%)	11.49	8.83	7.02	-1.35	11.96
Basic EPS (₹)	11.15	8.16	5.89	-0.83	7.35

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	895.22	788.97	713.72	526.94	525.07
Total Revenue Growth (%)	13.47	10.54	35.45	0.36	-7.33
Total Expenses	778.95	695.65	647.39	521.39	456.42
Total Expenses Growth (%)	11.97	7.45	24.17	14.23	-4.02
Profit after Tax (PAT)	87.61	68.38	49.42	4.08	68.04
PAT Growth (%)	28.12	38.35	1,110.03	-94.00	11.60
Operating Profit Margin (%)	15.71	14.29	12.65	5.26	16.83
Net Profit Margin (%)	9.87	8.73	6.96	0.78	13.08
Basic EPS (₹)	9.58	8.07	5.84	0.48	8.04

All figures in Rs Cr, unless mentioned otherwise

Insights

Employee & Interest Expense
Company has spent 2.6% of its operating revenues towards interest expenses and 9.92% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	1,362.44	1,152.68	1,034.09	879.61	859.50
Total Assets Growth (%)	18.20	11.47	17.56	2.34	5.82
Total Liabilities	576.63	513.04	497.76	419.08	389.21
Total Liabilities Growth (%)	12.40	3.07	18.77	7.67	-3.10
Total Equity	785.81	639.64	536.33	460.53	470.29
Total Equity Growth (%)	22.85	19.26	16.46	-2.08	14.56
Current Ratio (x)	1.81	1.72	1.62	1.61	1.92
Total Debt to Equity (x)	0.46	0.49	0.52	0.55	0.55
Contingent Liabilities	0.00	21.45	49.91	132.30	138.21

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	1,381.00	1,186.10	1,068.25	914.18	882.97
Total Assets Growth (%)	16.43	11.03	16.85	3.53	6.39
Total Liabilities	576.21	513.03	497.76	419.08	389.21
Total Liabilities Growth (%)	12.32	3.07	18.77	7.67	-3.10
Total Equity	804.79	673.07	570.49	495.10	493.76
Total Equity Growth (%)	19.57	17.98	15.23	0.27	15.31
Current Ratio (x)	1.81	1.72	1.62	1.61	1.92
Total Debt to Equity (x)	0.45	0.46	0.49	0.51	0.53
Contingent Liabilities	0.00	21.45	49.91	132.30	138.21

All figures in Rs Cr, unless mentioned otherwise

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	59.22	81.71	50.12	22.45	40.23
Net Cash used in Investing Activities	-130.78	-123.43	-52.07	-29.69	-27.15
Net Cash flow from Financing Activities	76.03	47.08	30.68	-31.97	-6.92
Net Cash Flow	4.48	5.36	28.73	-39.21	6.16
Closing Cash & Cash Equivalent	45.88	41.40	36.04	7.38	46.58
Closing Cash & Cash Equivalent Growth (%)	10.82	14.87	388.49	-84.16	15.24
Total Debt/ CFO (x)	6.16	3.80	5.59	11.25	6.47

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	60.68	81.71	50.12	22.45	40.23
Net Cash used in Investing Activities	-132.33	-123.44	-52.07	-29.69	-27.15
Net Cash flow from Financing Activities	76.03	47.08	30.68	-31.97	-6.92
Net Cash Flow	4.39	5.35	28.73	-39.21	6.16
Closing Cash & Cash Equivalent	45.78	41.39	36.04	7.38	46.58
Closing Cash & Cash Equivalent Growth (%)	10.60	14.85	388.49	-84.16	15.24
Total Debt/ CFO (x)	6.02	3.80	5.59	11.25	6.47

All figures in Rs Cr, unless mentioned otherwise

Insights

Cash from Operations vs PAT
Operating cash flow of Rs 59.22 cr is 0.58 times compared to the reported net profit of Rs 101.99 cr. (Source: Consolidated Financials)
Increase in Cash from Investing
Company has used Rs 130.78 cr for investing activities which is an YoY increase of 5.96%. (Source: Consolidated Financials)

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	12.97	10.80	9.29	-1.53	13.23
Return on Capital Employed (%)	13.84	13.38	12.75	4.36	13.17
Return on Assets (%)	7.48	5.99	4.81	-0.80	7.23
Interest Coverage Ratio (x)	7.78	7.83	5.16	2.71	6.33
Asset Turnover Ratio (x)	0.71	0.72	0.74	0.60	0.61
Price to Earnings (x)	34.48	27.32	30.30	-69.44	12.77
Price to Book (x)	4.47	2.95	2.81	1.06	1.69
EV/EBITDA (x)	21.31	14.82	14.44	12.36	8.43
EBITDA Margin (%)	20.25	18.55	17.07	11.37	22.99

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	10.88	10.15	8.66	0.82	13.77
Return on Capital Employed (%)	13.54	12.98	12.19	4.16	12.75
Return on Assets (%)	6.34	5.76	4.62	0.44	7.70
Interest Coverage Ratio (x)	7.77	7.89	5.17	2.72	6.34
Asset Turnover Ratio (x)	0.69	0.69	0.72	0.58	0.61
Price to Earnings (x)	40.16	27.62	30.58	120.48	11.68
Price to Book (x)	4.36	2.80	2.64	0.99	1.61
EV/EBITDA (x)	21.35	14.72	14.41	12.32	8.42
EBITDA Margin (%)	20.21	18.67	17.10	11.41	23.02

Insights

ROE Outperforming 5 Year Average
Company delivered ROE of 12.97% in year ending Mar 31, 2026 outperforming its 5 year avg. of 9.55%. (Source: Consolidated Financials)

Found Financials useful?

Technicals

Buy/Sell Signals
No Data Available
Price Analysis
No Data Available
Pivot Levels
R1 - Pivot
-
S1 -
R2 - S2 -
R3 - S3 -
Average True Range
5 Days 14 Days 28 Days
- - -

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
SMS Pharma	34.77	4.51	12.97	13.84	7.48	19.11	15.75	9.92	11.15	1.81	0.46	6.16
Gujarat Themis	89.53	14.52	16.22	15.32	9.27	2.74	39.22	28.15	4.28	1.12	0.56	3.28
IOL Chemicals	27.77	2.13	7.65	11.07	5.32	1.42	9.06	5.93	4.69	1.78	0.07	0.62
RPG Life Sci	32.70	6.22	19.02	23.89	14.52	12.17	21.36	16.27	69.64	3.52	0.03	0.35
Gufic BioSci	55.48	5.36	9.65	14.93	4.78	10.83	13.04	6.80	6.40	1.55	0.58	8.57
Add More

Annual Ratios (%)

Choose from Peers

Aarti Drugs
Panacea Biotec
Unichem Labs
Solara Active Pharma
Morepen Labs

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

Shareholding Pattern

Total Shareholdings
Category No. of Shares Percentage % Change QoQ
Promoters 6,37,45,010 68.07 % 0.00
Pledge 1,14,66,740 17.99 % 0.00
FII 2,87,736 0.31 % 0.27
DII 28,18,764 3.01 % -0.20
MF 27,69,004 2.96 % -0.25
Others 2,68,00,520 28.61 % -0.07
QoQ Change
Category Mar 2026 Dec 2025 Sep 2025 Jun 2025
Promoters 68.07 68.07 68.07 66.26
Pledge 17.99 17.99 34.65 32.49
FII 0.31 0.04 0.28 0.03
DII 3.01 3.21 2.88 3.03
Mutual Funds 2.96 3.21 2.88 3.03
Others 28.61 28.68 28.77 30.67

Mutual Funds Ownership

MF Ownership as on 31 May 2026

Quant Small Cap Direct-G
Equity: Small Cap
3
- 68.67
  Amount Invested (in Cr.)
- 0.216118%
  % of AUM
- 0.00
  % Change (MoM basis)
Quant Healthcare Direct-G
Equity: Sectoral-Pharma
- 28.53
  Amount Invested (in Cr.)
- 7.659903%
  % of AUM
- 0.00
  % Change (MoM basis)
Motilal Oswal BSE Healthcare ETF-G
Equity: Sectoral-Pharma
- 0.03
  Amount Invested (in Cr.)
- 0.07%
  % of AUM
- -9.58
  % Change (MoM basis)

View all Mutual Fund Schemes

SMS Pharma Top Searches

Corporate Actions

Recent
Final
40%
May 22, 2026
Board Meeting
Audited Results & Final Dividend
May 18, 2026
Board Meeting
Quarterly Results
Feb 01, 2026

Announced on	Meeting on
May 18, 2026	May 22, 2026
Audited Results & Final Dividend
Feb 01, 2026	Feb 07, 2026
Quarterly Results
Nov 03, 2025	Nov 08, 2025
Quarterly Results
Aug 04, 2025	Aug 09, 2025
Quarterly Results & Others
May 23, 2025	May 30, 2025
Audited Results & Final Dividend

Dividends
Announced on Ex-Date Dividend%
May 30, 2025 Sep 22, 2025 40%
May 29, 2024 Sep 23, 2024 40%
May 24, 2023 Sep 22, 2023 30%
May 30, 2022 Sep 22, 2022 30%
May 22, 2026 - 40%
Bonus
No Data Available
Splits
Announced on Ex-Date
Oct 09, 2015 Dec 17, 2015
Split: Old FV10.0| New FV:1.0
Rights
No Data Available
AGM/EGM Meetings
Announced on Meeting on
Sep 09, 2025 Sep 29, 2025
-
Aug 05, 2024 Sep 30, 2024
Book closure from Sep 24, 2024 to Sep 30, 2024
Feb 13, 2024 Mar 06, 2024
-
Aug 08, 2023 Sep 30, 2023
A.G.M.
Jul 11, 2023 Aug 12, 2023
-

About SMS Pharma

SMS Pharmaceuticals Ltd., incorporated in the year 1987, is a Small Cap company (having a market cap of Rs 3,545.67 Crore) operating in Pharmaceuticals sector.

SMS Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services, Export Incentives and Conversion Charges for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 240.52 Crore, up 12.29 % from last quarter Total Income of Rs 214.20 Crore and down 3.64 % from last year same quarter Total Income of Rs 249.62 Crore. Company has reported net profit after tax of Rs 20.96 Crore in latest quarter.

The company’s top management includes Mr.Ramesh Babu Potluri, Mr.Vamsi Krishna Potluri, Dr.Sunkara Venkata Satya Shiva Prasad, Mr.Trilok Potluri, Mr.Sarvepalli Srinivas, Mrs.Shanti Sree Bolleni, Mr.Sharvan Kudaravalli, Dr.Suresh Kumar Gangavarapu, Mr.Lakshmi Narayana Tammineedi, Mr.Thirumalesh Tumma. Company has Suryanarayana & Suresh as its auditors. As on 31-03-2026, the company has a total of 9.37 Crore shares outstanding.

SMS Pharma Share Price Today is Rs. 378.60. On previous day, the SMS Pharma Share Price (NSE) closed at Rs. 374.15, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 68.07% of the stake in SMS Pharma shares, out of which 17.99% was pledged. On the same date, foreign institutional investors' (FII) holdings of SMS Pharma stocks was 0.31% as compared to 0.04% in Dec 2025 with increase of 0.27%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 3.01% as compared to 3.21% in Dec 2025 with decrease of 0.2%. Out of the total DII holdings in SMS Pharma shares 2.96% was held by mutual funds. The rest including public held is 28.61%. SMS Pharma stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
SMS Pharma Dividend: Ever since 1987, SMS Pharma dividends has been paid out around 19 times. As on 19 Jun, 2026, 03:54 PM IST, The overall dividend yield for SMS Pharma stands at 0.11%. The last dividend paid was on September 22, 2025 (Rs. 0.4). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 10.89.

SMS Pharma Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 240.52 Cr. of sales and 12.29% of quarterly net profit, there have been multiple ups and downs in the SMS Pharma stock prices in the past few weeks. For example, SMS Pharma stock price on 12th of June 2026 was around Rs. 383.45. SMS Pharma share price now stands at an average of Rs. 378.60. Judging by last week's performance, stock is in down trend.

SMS Pharma has a median target price of Rs. 0.0 in 12 months by 0 analysts. They have provided a high estimate of Rs. 0.0 and low estimate of Rs. 0.0 for SMS Pharma share.

Historical Prices and Performance:
SMS Pharma, incorporated in 1987 is a Small Cap company (with a market cap of Rs. 3545.67) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by SMS Pharma stock was 12.97%, 10.8%, 9.29%, -1.53% and 13.23% respectively.
The SMS Pharma share gave a 3 year return of 310.85% as compared to Nifty 50 which gave a return of 28.03%.
SMS Pharma announced 40.0% final dividend on September 22, 2025.

Key Metrics:
PE Ratio of SMS Pharma is 34.77
Prices/Sales Ratio of SMS Pharma is 3.96
Price/Book Ratio of SMS Pharma is 4.51

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For SMS Pharma, major competitors and peers include Gujarat Themis, IOL Chemicals, RPG Life Sci and Gufic BioSci. As of Dec 2025, the dividend yield of SMS Pharma stands at 0.11% while Gujarat Themis, IOL Chemicals, RPG Life Sci and Gufic BioSci stand at 0.17%, 0.77%, 1.05% and 0.03% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 34.77 and 4.51 respectively.

Leadership of SMS Pharma :
Thirumalesh Tumma is Co. Secretary & Compl. Officer
Lakshmi Narayana Tammineedi is Chief Financial Officer
Ramesh Babu Potluri is Chairman & Managing Director
Vamsi Krishna Potluri is Executive Director
Sunkara Venkata Satya Shiva Prasad is Non Exe.Non Ind.Director
Trilok Potluri is Non Exe.Non Ind.Director
Sarvepalli Srinivas is Ind. Non-Executive Director
Sharvan Kudaravalli is Ind. Non-Executive Director
Suresh Kumar Gangavarapu is Ind. Non-Executive Director
Shanti Sree Bolleni is Ind. Non-Executive Director

Show More

Industry

Pharma - Indian

Key Indices Listed On

BSE SmallCap, BSE Healthcare, BSE AllCap, BSE MidSmallCap

Address

Plot No. 72, H.No. 8-2-334 / 3 & 4,Road No. 5, Opp. SBI Executive Enclave,Banjara Hills,Hyderabad, Telangana - 500034

Contact

info@smspharma.com

http://www.smspharma.com

Executive Leadership

RB

Ramesh Babu Potluri

Chairman & Managing Director

VK

Vamsi Krishna Potluri

Executive Director

SV

Sunkara Venkata Satya Shiva Prasad

Non Exe.Non Ind.Director

TP

Trilok Potluri

Non Exe.Non Ind.Director

Show More

Auditors

Suryanarayana & Suresh

FAQs about SMS Pharma share

1. What's the SMS Pharma share price today?
SMS Pharma share price is Rs 378.60 as on 19 Jun, 2026, 03:54 PM IST. SMS Pharma share price is up by 1.19% based on previous share price of Rs. 375.95.
2. What's the market capitalization of SMS Pharma?
SMS Pharma share has a market capitalization of Rs 3,545.67 Cr. Within Pharmaceuticals sector, it's market cap rank is 67.
3. What has been highest price of SMS Pharma share in last 52 weeks?
SMS Pharma share price saw a 52 week high of Rs 447.80 and 52 week low of Rs 207.70.
4. What is the PE & PB ratio of SMS Pharma?
The PE ratio of SMS Pharma stands at 34.36, while the PB ratio is 4.46.
5. What are the returns for SMS Pharma share?
Return Performance of SMS Pharma Shares:
- 1 Week: SMS Pharma share price moved down by 1.26%

Top Gainers

As on 03:57 PM | 19 Jun 2026

971.70

657.90 (209.66%)

Netweb Technologies

5,060.90

3254.10 (180.10%)

Syrma SGS Technology

1,334.00

805.00 (152.17%)

5,533.50

3224.90 (139.69%)

209.61

121.58 (138.11%)

Top Losers

As on 03:59 PM | 19 Jun 2026

Tata Investment

691.00

-6193.00 (-89.96%)

353.70

-2663.90 (-88.28%)

399.25

-1727.55 (-81.23%)

823.15

-3249.55 (-79.79%)

Authum Investment

543.80

-1954.00 (-78.23%)

Equity Quick Links

Top Gainers
Top Losers
Hourly gainers
Hourly losers
Sensex
Nifty
NSE
BSE

Midcap stocks
Smallcap stocks
Largecap stocks
Sensex
Nifty
NSE
BSE
MCX Live

More from Markets

IPO
Stock market news
Budget 2022 Live Updates
Cryptocurrency
Currency converter
NSE holiday list

Trending in Markets

DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

By using this site, you agree to the Terms of Service and Privacy Policy.